PMID- 35155187
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220216
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Ethyl Ferulate Suppresses Esophageal Squamous Cell Carcinoma Tumor Growth Through 
      Inhibiting the mTOR Signaling Pathway.
PG  - 780011
LID - 10.3389/fonc.2021.780011 [doi]
LID - 780011
AB  - Ethyl ferulate is a phenylpropanoid compound isolated from the medicinal herb 
      Ferula. Although ethyl ferulate has anti-inflammatory, antioxidant, and 
      neuroprotective activities with potential use in the nutraceutical and 
      pharmaceutical industry, its anticancer effects and underlying molecular 
      mechanisms against esophageal squamous cell carcinoma (ESCC) have not been 
      investigated. This study investigates the anticancer activity and molecular 
      mechanism of ethyl ferulate in ESCC. MTT, focus formation, soft agar, and cell 
      cycle analysis were used to determine the effect of ethyl ferulate on cell 
      proliferation and cell cycle. Potential candidate proteins were screened and 
      verified via Western blotting, in vitro kinase assay, and in vitro pull-down 
      assay. Mammalian target of rapamycin (mTOR) knockdown cell lines were established 
      by lentiviral infection with shmTOR. The effect of ethyl ferulate on tumor growth 
      was assessed using ESCC patient-derived xenograft models. Ethyl ferulate 
      significantly inhibited cell growth and induced G1 phase cell cycle arrest in 
      ESCC cells. Ethyl ferulate reduced the activity of mTOR in vitro. The inhibition 
      of ESCC cell growth by ethyl ferulate is dependent on mTOR expression. In 
      addition, ethyl ferulate strongly reduced ESCC patient-derived xenograft tumor 
      growth in an in vivo mouse model. Ethyl ferulate is an mTOR inhibitor that can 
      suppress ESCC progression and may be a novel candidate compound for esophageal 
      cancer chemoprevention.
CI  - Copyright (c) 2022 Pang, Xie, Zhang, Laster, Liu and Kim.
FAU - Pang, Mengjun
AU  - Pang M
AD  - The Pathophysiology Department, The School of Basic Medical Sciences, Zhengzhou 
      University, Zhengzhou, China.
AD  - China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
FAU - Xie, Xiaomeng
AU  - Xie X
AD  - The Pathophysiology Department, The School of Basic Medical Sciences, Zhengzhou 
      University, Zhengzhou, China.
AD  - China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
FAU - Zhang, Yuanyuan
AU  - Zhang Y
AD  - China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
AD  - Translational Research Institute, Henan Provincial People's Hospital, Academy of 
      Medical Science, Zhengzhou University, Zhengzhou, China.
FAU - Laster, Kyle Vaughn
AU  - Laster KV
AD  - China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
FAU - Liu, Kangdong
AU  - Liu K
AD  - The Pathophysiology Department, The School of Basic Medical Sciences, Zhengzhou 
      University, Zhengzhou, China.
AD  - China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
AD  - Provincial Cooperative Innovation Center for Cancer Chemoprevention, Zhengzhou 
      University, Zhengzhou, China.
AD  - The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, 
      Zhengzhou, China.
AD  - International Joint Research Center of Cancer Chemoprevention, Zhengzhou, China.
FAU - Kim, Dong Joon
AU  - Kim DJ
AD  - The Pathophysiology Department, The School of Basic Medical Sciences, Zhengzhou 
      University, Zhengzhou, China.
AD  - China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
AD  - The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, 
      Zhengzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220128
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8833257
OTO - NOTNLM
OT  - cancer growth
OT  - esophageal squamous cell carcinoma
OT  - ethyl ferulate
OT  - mTOR
OT  - patient-derived xenograft
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/15 06:00
MHDA- 2022/02/15 06:01
PMCR- 2021/01/01
CRDT- 2022/02/14 05:34
PHST- 2021/09/20 00:00 [received]
PHST- 2021/12/27 00:00 [accepted]
PHST- 2022/02/14 05:34 [entrez]
PHST- 2022/02/15 06:00 [pubmed]
PHST- 2022/02/15 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.780011 [doi]
PST - epublish
SO  - Front Oncol. 2022 Jan 28;11:780011. doi: 10.3389/fonc.2021.780011. eCollection 
      2021.